Cargando…
Never too old to fight breast cancer: A case report
RATIONALE: Breast cancer is the most common cancer affecting females worldwide and its lifetime risk increases with age. Human epidermal growth factor receptor gene-2 (HER-2) positive breast cancer represents about 20% of all breast cancers, 1 out of 10 is diagnosed in women over 70 years of age. It...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5851756/ https://www.ncbi.nlm.nih.gov/pubmed/29489698 http://dx.doi.org/10.1097/MD.0000000000009981 |
_version_ | 1783306450540429312 |
---|---|
author | Zuradelli, Monica Masci, Giovanna Ferraro, Emanuela Losurdo, Agnese De Sanctis, Rita Torrisi, Rosalba Santoro, Armando |
author_facet | Zuradelli, Monica Masci, Giovanna Ferraro, Emanuela Losurdo, Agnese De Sanctis, Rita Torrisi, Rosalba Santoro, Armando |
author_sort | Zuradelli, Monica |
collection | PubMed |
description | RATIONALE: Breast cancer is the most common cancer affecting females worldwide and its lifetime risk increases with age. Human epidermal growth factor receptor gene-2 (HER-2) positive breast cancer represents about 20% of all breast cancers, 1 out of 10 is diagnosed in women over 70 years of age. It tends to be more aggressive and to spread more quickly than other subtypes, but the introduction in clinical practice of new anti-HER-2 agents combined with chemotherapy has significantly improved progression free and overall survival. Elderly patients are frequently undertreated because of concerns about their age, performance status, and comorbidities. Here, we report a case of an octogenarian patient treated with T-DM1 with brilliant results. PATIENT CONCERNS: An 87 years old woman affected with HER-2 positive breast cancer presented progression of disease with lymph node and skin metastases after 3 lines of chemoimmunotherapy. DIAGNOSES: Breast cancer in elderly patient, lymph node, and skin metastases. INTERVENTIONS: Chemoimmunotherapy (trastuzumab emtansine). OUTCOME: Objective response of the disease and significant clinical benefit. LESSONS: This case clearly suggests that age and comorbidities do not always represent an absolute contraindication to combined treatments. |
format | Online Article Text |
id | pubmed-5851756 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Wolters Kluwer Health |
record_format | MEDLINE/PubMed |
spelling | pubmed-58517562018-03-21 Never too old to fight breast cancer: A case report Zuradelli, Monica Masci, Giovanna Ferraro, Emanuela Losurdo, Agnese De Sanctis, Rita Torrisi, Rosalba Santoro, Armando Medicine (Baltimore) 5700 RATIONALE: Breast cancer is the most common cancer affecting females worldwide and its lifetime risk increases with age. Human epidermal growth factor receptor gene-2 (HER-2) positive breast cancer represents about 20% of all breast cancers, 1 out of 10 is diagnosed in women over 70 years of age. It tends to be more aggressive and to spread more quickly than other subtypes, but the introduction in clinical practice of new anti-HER-2 agents combined with chemotherapy has significantly improved progression free and overall survival. Elderly patients are frequently undertreated because of concerns about their age, performance status, and comorbidities. Here, we report a case of an octogenarian patient treated with T-DM1 with brilliant results. PATIENT CONCERNS: An 87 years old woman affected with HER-2 positive breast cancer presented progression of disease with lymph node and skin metastases after 3 lines of chemoimmunotherapy. DIAGNOSES: Breast cancer in elderly patient, lymph node, and skin metastases. INTERVENTIONS: Chemoimmunotherapy (trastuzumab emtansine). OUTCOME: Objective response of the disease and significant clinical benefit. LESSONS: This case clearly suggests that age and comorbidities do not always represent an absolute contraindication to combined treatments. Wolters Kluwer Health 2018-03-02 /pmc/articles/PMC5851756/ /pubmed/29489698 http://dx.doi.org/10.1097/MD.0000000000009981 Text en Copyright © 2018 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nd/4.0 This is an open access article distributed under the Creative Commons Attribution-No Derivatives License 4.0, which allows for redistribution, commercial and non-commercial, as long as it is passed along unchanged and in whole, with credit to the author. http://creativecommons.org/licenses/by-nd/4.0 |
spellingShingle | 5700 Zuradelli, Monica Masci, Giovanna Ferraro, Emanuela Losurdo, Agnese De Sanctis, Rita Torrisi, Rosalba Santoro, Armando Never too old to fight breast cancer: A case report |
title | Never too old to fight breast cancer: A case report |
title_full | Never too old to fight breast cancer: A case report |
title_fullStr | Never too old to fight breast cancer: A case report |
title_full_unstemmed | Never too old to fight breast cancer: A case report |
title_short | Never too old to fight breast cancer: A case report |
title_sort | never too old to fight breast cancer: a case report |
topic | 5700 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5851756/ https://www.ncbi.nlm.nih.gov/pubmed/29489698 http://dx.doi.org/10.1097/MD.0000000000009981 |
work_keys_str_mv | AT zuradellimonica nevertoooldtofightbreastcanceracasereport AT mascigiovanna nevertoooldtofightbreastcanceracasereport AT ferraroemanuela nevertoooldtofightbreastcanceracasereport AT losurdoagnese nevertoooldtofightbreastcanceracasereport AT desanctisrita nevertoooldtofightbreastcanceracasereport AT torrisirosalba nevertoooldtofightbreastcanceracasereport AT santoroarmando nevertoooldtofightbreastcanceracasereport |